In today’s briefing:
- PureTech Health (PRTC LN): Possible Combination with Nektar Is Just a Defensive Move
- Recognizing Human Resource Strategy as a Management Issue and Creating the Policy Is the First Step
- Wuxi Biologics (2269.HK) – Removed from UVL, but the Crisis Is Not Over
- Giant Biogene Pre-IPO – PHIP Updates – Sales Growing Faster but so Have Marketing Spends
PureTech Health (PRTC LN): Possible Combination with Nektar Is Just a Defensive Move
- PureTech Health (PRTC LN) has confirmed its possible merger with Nektar Therapeutics (NKTR US). Uncertainty regarding the actual offer has caused volatility to PureTech shares.
- Nektar will be required, by not later than November 3, 2022, to announce a firm intention to make an offer for the company.
- Nektar faced a big setback in its lead pipeline assets and is going through tight financial condition. We are not expecting a lucrative takeover offer for PureTech.
Recognizing Human Resource Strategy as a Management Issue and Creating the Policy Is the First Step
- Neither the company nor the employees have made sufficient investments, despite the fact that both sides see a gap between the skills they need and the reality.
- Many companies either fail to link their management strategy to their human capital investment and human resource strategy, or don’t have a clear policy for human capital investment.
- If investment in human resources is curbed in order to maintain short-term profit margins, this will lead to weighing on growth potential and profit margins in the medium-to-long term.
Wuxi Biologics (2269.HK) – Removed from UVL, but the Crisis Is Not Over
- Wuxi Biologics (2269 HK) has been removed from the “Unverified List”, but the crisis is not over. CXO’s valuation center could gradually volatile to the downside,during which there would be temporary rebounds.
- Biotechnology of US and China has entered a higher level of game. As domestic CXO is deeply embedded in global supply chain, we won’t take any chances on WuXi Biologics.
- We may face a long high-interest-rate environment after the Fed hikes,but the booming of US pharmaceutical IPOs is the underlying logic of CXO. We provided suggestions on CXO trading strategy.
Giant Biogene Pre-IPO – PHIP Updates – Sales Growing Faster but so Have Marketing Spends
- Giant Biogene Holding (GBH HK) aims to raise around US$500m in its Hong Kong IPO.
- GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
- We had looked at the company’s past performance in our previous notes. In this note, we’ll talk about its PHIP updates.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
